Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026)
Denali Therapeutics (DNLI) posted quarterly Non-Current Assets of $243.3 million for Q1 2026, down 38.05% year-over-year from $392.7 million in Q1 2025, and little changed quarter-over-quarter from $244.2 million in Q4 2025.
Denali Therapeutics (DNLI) Non-Current Assets (2017 - 2026) Analysis & Trends
Denali Therapeutics (DNLI) has reported Non-Current Assets for 10 consecutive years, with $243.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 38.05% year-over-year to $243.3 million; the TTM figure through Mar 2026 stood at $892.0 million (down 56.74% YoY), while the FY2025 annual figure was $244.2 million, down 52.09% from the prior year.
- Non-Current Assets held at $243.3 million in Q1 2026 per DNLI's latest filing, from $244.2 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $607.5 million in Q1 2024 and bottomed at $81.7 million in Q2 2023.
- Historically, Non-Current Assets has averaged $270.5 million across 5 years, with a median of $231.5 million in 2025.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 82.66% — and 2024, when it jumped 621.67%.
- Denali Therapeutics' Non-Current Assets stood at $87.9 million in 2022, then advanced by 2.11% to $89.8 million in 2023, then surged by 467.77% to $509.7 million in 2024, then sank by 52.09% to $244.2 million in 2025, then retreated by 0.38% to $243.3 million in 2026.
- Business Quant data shows DNLI's Non-Current Assets at $243.3 million in Q1 2026, $244.2 million in Q4 2025, and $173.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Denali Therapeutics | 3.90 Bn | 3.90 Bn | 3.51 Mn | 404.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 404.03 Mn |
| Mar 31, 2026 | 243.27 Mn |
| Dec 31, 2025 | 244.20 Mn |
| Sep 30, 2025 | 173.02 Mn |
| Jun 30, 2025 | 231.54 Mn |
| Mar 31, 2025 | 392.71 Mn |
| Dec 31, 2024 | 509.74 Mn |
| Sep 30, 2024 | 585.17 Mn |
| Jun 30, 2024 | 574.18 Mn |
| Mar 31, 2024 | 607.52 Mn |
| Dec 31, 2023 | 89.78 Mn |
| Sep 30, 2023 | 93.89 Mn |
| Jun 30, 2023 | 81.67 Mn |
| Mar 31, 2023 | 84.18 Mn |
| Dec 31, 2022 | 87.92 Mn |
| Sep 30, 2022 | 89.08 Mn |
| Jun 30, 2022 | 177.86 Mn |
| Mar 31, 2022 | 332.42 Mn |
| Dec 31, 2021 | 506.93 Mn |
| Sep 30, 2021 | 394.46 Mn |